Comparison of Total Parathyroidectomy With and Without Autotransplantation
Launched by THE SECOND HOSPITAL OF ANHUI MEDICAL UNIVERSITY · Aug 26, 2015
Trial Information
Current as of May 23, 2025
Unknown status
Keywords
ClinConnect Summary
Background:Secondary hyperparathyroidism (SHPT) is a common disorder in patients with chronic kidney disease. It is caused by permanent stimulation of the orthotopic and heterotopic parathyroid tissue due to phosphate retention, hypocalcemia, and vitamin D insufficiency. Despite the initiation of new therapeutic agents, several patients will require parathyroidectomy.There are three options for the surgical treatment of SHPT:subtotal PTX (3.5-gland resection,SPTX), total PTX with autotransplantation(TPTX+AT), and total PTX without autotransplantation(TPTX).SPTX and TPTX+AT both leave a frag...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Both male and female, aged 18 or older;
- • Intact parathyroid hormone(iPTH) is more than 9 times the upper limit of the normal range (about 600pg/ml), with hypercalcemia or hyperphosphatemia;
- • Refractory to medical therapy;
- • Provided written informed consent.
- Exclusion Criteria:
- • Primary or tertiary hyperparathyroidism;
- • Familial hyperparathyroidism (MENⅠ, MENⅡ, hereditary HPT);
- • Neck surgical exploration history;
- • Parathyroid malignant tumor.
About The Second Hospital Of Anhui Medical University
The Second Hospital of Anhui Medical University is a leading healthcare institution in China dedicated to advancing medical research and improving patient care. As a prominent clinical trial sponsor, the hospital is committed to conducting rigorous and innovative research that adheres to the highest ethical standards. It leverages its multidisciplinary expertise and state-of-the-art facilities to facilitate the development of new therapies and interventions, contributing significantly to the global medical community. By fostering collaboration among researchers, clinicians, and industry partners, the Second Hospital aims to translate scientific discoveries into tangible health solutions for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hefei, Anhui, China
Patients applied
Trial Officials
xiaoping geng, professor
Principal Investigator
the vice President of the second affiliated hospitalof Anhui medical university
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials